Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Post by Bucknelly21on May 12, 2021 6:16pm
213 Views
Post# 33188320

Tomorrow

Tomorrow I think for me tomorrow is make or break. I refuse to sit back and have my money invested in a company that doesn't put shareholders interest at the top of the list. We will see. Of course the life science people will help. But the attitude has to change within the company not just trying to buy a correction. Some will say by outsourcing the research paper to gain interest is just that, I disagree. It can be the best paper ever written but if management and the board are so unwilling to change the. It will be more wasted money and time. They need to start tomorrow by being honest and forthright. " we messed up a few things as far as getting the attention of Capital markets" ect. I'm at the very end of my rope with these guys. It appears to be more of the same ahead as no prs to build some excitement around tomorrow this week or last. They just don't get it. And I intend to put my money to work before the bull market ends rather than letting it collect dust waiting on Thera to get its act together and start acting like they are on their way to becoming a global pharma company. You would never see such old inaccuracies on a website of Merck, jnj ect it's honestly embarrassing 
<< Previous
Bullboard Posts
Next >>